What happened in optometry this week: March 4 - March 8
Catch up on what happened in optometry during the week of March 4-March 8.
Catch up with what Optometry Times shared this week:
FDA approves clobetasol propionate 0.05% for ocular pain, inflammation following surgery
By Sydney M Crago, Editor, Modern Retina; Hattie Hayes; and Emily Kaiser Maharjan, Assistant Managing Editor
The US Food and Drug Administration (FDA) has approved clobetasol propionate ophthalmic suspension 0.05% (APP13007) by Taiwan-based Formosa Pharmaceuticals and AimMax Therapeutics. This suspension for the treatment of post-operative inflammation and pain following ocular surgery is the first FDA-approved ophthalmic clobetasol propionate product and first new steroid on the ophthalmic market in over 15 years.
Study finds similar pathogenic pathways in AMD and some cancers
By Lynda Charters
Junhee Park, MD, and associates reported a possible association between several cancers and age-related macular degeneration (AMD) that they identified in a population-based cohort study.1 Park is from the Family Medicine Department, Samsung Medical Center, Seoul, South Korea.
EVO ICLs versus LASIK with Dr Eric Fazio
By Emily Kaiser Maharjan, Assistant Managing Editor; Eric Fazio, OD; and Jordana Joy, Associate Editor
Exciting new developments in vision correction have taken the form of EVO ICLs, or implantable collamer lens, that can provide an alternative treatment route for patients. Eric Fazio, OD, sat down with Optometry Times to discuss the pros and cons between ICL and laser-assisted in situ keratomileusis (LASIK) treatments.
The role ferroptosis plays in bacterial keratitis development
By Lynda Charters
Chinese investigators, led by first author Qiankun Chen, MD, recently reported identifying that ferroptosis “plays a crucial role in the pathogenesis of bacterial keratitis,” and inhibiting ferroptosis is promising to reduce inflammation and corneal scarring, and enhance the disease prognosis.
One last hurrah: Vision Expo East celebrates last year in New York
By Jordana Joy, Associate Editor and Ashley Mills
There is a lot to be excited about for the upcoming Vision Expo East event, according to The Vision Council CEO Ashley Mills. 2024 marks the last year that the event will take place in New York, which is slated to run from March 14 to 17. 2025 will be the event's first year in Florida, a decision made in order to appeal to market, consumer, and eye care provider demands. Mills sat down with Optometry Times to discuss what she thinks will be this year's highlights at the event.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
